Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

NCT06772168 is registered in ClinicalTrials.gov with CMG Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT06772168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06772168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
Lead sponsor
CMG Pharmaceutical Co. Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
April 19, 2024
Completion date
February 1, 2027
Enrollment
240 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia, type 2 diabetes